share_log

QHSLab Integrates Digital Medicine Assessments Into Prominent Electronic Health Record (EHR) Company

QHSLab Integrates Digital Medicine Assessments Into Prominent Electronic Health Record (EHR) Company

QHSlab 將數字醫學評估整合到著名的電子健康記錄 (EHR) 公司中
GlobeNewswire ·  01/30 21:30

This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers.

這種集成允許QHSlab訪問超過160,000家與目標提供商完全匹配的提供商。

WEST PALM BEACH, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, is proud to announce the seamless integration of its digital medicine assessments with one of the nation's top Electronic Health Record (EHR) Company. This update demonstrates promising growth for QHSLab in its mission to revolutionize provider workflow and elevate the quality of patient care.

佛羅里達州西棕櫚灘,2024年1月30日(GLOBE NEWSWIRE)——QHSlab, Inc.(“公司”)(OTCQB:USAQ)是一家專注於通過新興的數字醫療和即時醫療技術爲臨床醫生提供工具的公司,該公司自豪地宣佈其數字醫學評估與美國頂級電子健康記錄(EHR)公司之一無縫整合。此次更新表明,QHSlab在革新提供者工作流程和提高患者護理質量的使命方面取得了可觀的發展。

The more than 160,000 providers utilizing this EHR system will now have direct access to QHSLab's comprehensive suite of digital medicine assessments and monitoring tools, such as self-management patient education interventions designed to offer healthcare providers a comprehensive view of their patient's total health. As an added benefit, these practitioners will also have point-of-care testing kits for one of today's most common complaints in general medicine – allergies. With the addition of the AllergiQT, physicians can confirm a patient's allergies with an easy in-office allergy skin test in less than 20 minutes.

現在,使用該EHR系統的160,000多家提供商將可以直接訪問QHSlab的全套數字醫學評估和監測工具,例如旨在爲醫療保健提供者提供患者總體健康狀況的自我管理患者教育干預措施。作爲額外的好處,這些從業者還將爲當今普通醫學中最常見的症狀之一——過敏提供即時檢測試劑盒。加入 AllergiQT 後,醫生可以在不到 20 分鐘的時間內通過簡單的辦公室皮膚過敏測試來確認患者的過敏情況。

Key Advantages for Providers and Patients:

提供者和患者的主要優勢:

Enhanced Efficiency: Providers will now seamlessly access and review patient assessments within the EHR, negating the need to switch between multiple platforms. This integration simplifies workflow, saving crucial time and reducing administrative burdens, providing healthcare professionals with the bandwidth for better patient care.

提高效率:提供商現在將無縫訪問和審查EHR中的患者評估,無需在多個平台之間切換。這種集成簡化了工作流程,節省了關鍵時間並減輕了管理負擔,爲醫療保健專業人員提供了更好的患者護理所需的帶寬。

Informed Decision-Making: Integrating QHSLab's digital assessments within the EHR guarantees providers immediate access to comprehensive patient data. This empowers clinicians to make well-informed decisions, translating into more personalized and effective patient care plans.

知情決策:將QHSlab的數字評估集成到EHR中可確保提供商立即訪問全面的患者數據。這使臨床醫生能夠做出明智的決定,轉化爲更加個性化和有效的患者護理計劃。

Real-Time Updates: Patient health is dynamic, and QHSLab provides an ongoing snapshot of a patient's reported feedback and complaints in real time. Patient data remains consistently updated, with changes in QHSLab's assessments automatically reflected in the EHR. This ensures healthcare providers can access the most current information when making clinical decisions and care coordination treatment plans.

實時更新:患者健康狀況是動態的,qhsLab實時提供患者報告的反饋和投訴的持續快照。患者數據保持持續更新,QHSlab評估的變化會自動反映在EHR中。這確保了醫療保健提供者在制定臨床決策和護理協調治療計劃時可以訪問最新的信息。

Seamless Collaboration: The integration fosters a collaborative approach to patient care. Providers can easily share and access patient assessments, nurturing a more connected healthcare ecosystem.

無縫協作:這種整合促進了患者護理的協作方法。提供商可以輕鬆共享和訪問患者評估,從而培育更加互聯的醫療保健生態系統。

Patient Engagement: Through QHSLab's digital assessments, patients actively engage in their healthcare journey. They can effortlessly complete assessments from their homes, making healthcare more convenient and accessible. This active involvement has the potential to yield superior patient outcomes. QHSLab also offers a suite of reimbursable assessments and interventions that allow practices to sustain themselves with a new revenue stream through the Company's proven CPT code reimbursement strategy.

患者參與:通過QHSlab的數字評估,患者積極參與他們的醫療之旅。他們可以毫不費力地在家中完成評估,從而使醫療保健更加便捷和可及。這種積極參與有可能爲患者帶來更好的預後。QHSlab還提供了一套可報銷的評估和干預措施,使診所能夠通過公司久經考驗的CPT代碼報銷策略維持生計,獲得新的收入來源。

Troy Grogan, Chief Executive Officer at QHSLab, expressed his enthusiasm about this integration: "This collaboration represents a significant milestone for QHSLab. By merging our digital medicine services with EHRs of this caliber, we're redefining how healthcare providers deliver patient care and reaching a broad, new audience for our platform. We've demonstrated a proven track record of success over the past 12 months, and this integration sets the stage for the next chapter of growth during 2024 and beyond."

QHSlab首席執行官特洛伊·格羅根表達了他對這種整合的熱情:“這次合作對QHSlab來說是一個重要的里程碑。通過將我們的數字醫療服務與這種水準的電子健康紀錄合併,我們正在重新定義醫療保健提供商如何提供患者護理併爲我們的平台吸引廣泛的新受衆。在過去的12個月中,我們取得了良好的成功記錄,這種整合爲2024年及以後的下一個增長篇章奠定了基礎。”

For more information about QHSLab, please visit

有關 QHSlab 的更多信息,請訪問

About QHSLab, Inc.

關於 QHSlab, Inc.

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.

QHSlab, Inc.(OTCQB:USAQ)是一家醫療器械公司,爲初級保健醫生提供數字醫療解決方案和即時診斷測試。數字醫療保健使醫生能夠使用先進的人工智能算法快速有效地評估患者的反應。數字醫療還可以通過患者之間傳輸的實時數據,遠程監控患者的生命體徵,評估處方藥和治療對患者健康的影響。QHSlab, Inc. 還營銷和銷售用於初級保健實踐的即時快速反應診斷測試。qHSlab, Inc. '的產品和服務旨在幫助醫生改善患者監測和醫療護理,同時提高他們的診所收入。

Forward-Looking Statements

前瞻性陳述

Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

本新聞稿中討論的某些事項是 “前瞻性陳述”,旨在使他們有資格獲得安全港,免於承擔1995年《私人證券訴訟改革法》規定的責任。特別是,公司關於市場趨勢、未來收入、未來產品以及潛在未來業績和收購的陳述就是此類前瞻性陳述的示例。前瞻性陳述通常用 “可能”、“可能”、“相信”、“估計”、“目標”、“預期” 或 “打算” 等詞語以及其他表達風險和不確定性的類似詞語來識別。這些陳述受到許多風險和不確定性的影響,包括但不限於新產品的推出時間、管理層的估計、預測和預測與實際業績的固有差異、監管延誤、政府資金和預算的變化以及公司無法控制的其他因素,包括總體經濟狀況。本文討論並在公司向美國證券交易委員會提交的文件中不時表達的因素可能導致實際業績和發展與此類聲明中表達或暗示的業績和發展存在重大差異。前瞻性陳述僅在本新聞稿發佈之日作出。公司沒有義務公開更新此類前瞻性陳述以反映隨後的事件或情況。

Investor Relations Contact:

投資者關係聯繫人:

Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com

奧利維亞·賈曼科
qHSlab, Inc.
(929) 379-6503
ir@usaqcorp.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論